Table 3.
Univariate and multivariate analyses of factors associated with complicated chemotherapy-induced diarrhea
| Factor | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p | OR | 95% CI | p | |
| Cancer sites, stomach (/colorectum) | 2.53 | 1.17–5.47 | 0.01 | 1.38 | 0.55–3.47 | 0.48 |
| Sex, female (/male) | 1.39 | 0.67–2.88 | 0.37 | |||
| Age, ≥ 70 (/< 70) | 1.26 | 0.58–2.72 | 0.54 | |||
| PS, 0–1 (/ ≥ 2) | 1.03 | 0.38–2.76 | 0.94 | |||
| Resection of primary sites, no (/yes) | 2.42 | 0.72–8.11 | 0.15 | |||
| Number of metastatic sites, 0–1 (≥ 2) | 1.75 | 0.85–3.59 | 0.12 | |||
| Fluoropyrimidine type*, oral (/infusional) | 3.59 | 1.52–8.47 | 0.003 | 2.95 | 1.06–8.19 | 0.03 |
| Combination chemotherapy, yes (/no) | 0.78 | 0.29–2.11 | 0.63 | |||
| Platinum, yes (/no) | 0.92 | 0.41–2.05 | 0.84 | |||
| Irinotecan, yes (/no) | 2.52 | 0.82–7.71 | 0.10 | |||
| Taxane, yes (/no) | 0.32 | 0.04–2.46 | 0.27 | |||
| Trastuzumab, yes (/no) | 0.95 | 0.21–4.15 | 0.94 | |||
| Cetuximab/panitumumab, yes (/no) | 0.43 | 0.05–3.26 | 0.41 | |||
| Bevacizumab, yes (/no) | 0.65 | 0.24–1.74 | 0.39 | |||
OR odds ratio, CI confidence interval, PS performance status
*Oral fluoropyrimidine includes S-1 or capecitabine, and intravenous fluoropyrimidine includes 5-fluorouracil